Sleeping through the night: Are extended-release formulations the answer?

Journal of the American Academy of Nurse Practitioners

Volumn 20, Issue 2, 2008, Pages 69-75

  Calamaro, Christina ^a  

^a DREXEL UNIVERSITY   (United States)

Author keywords

Insomnia; Sleep maintenance difficulties; Sleep onset difficulties; Zolpidem extended release

Indexed keywords

HYPNOTIC SEDATIVE AGENT; PYRIDINE DERIVATIVE; ZOLPIDEM;

CHEMISTRY; DELAYED RELEASE FORMULATION; DRUG MONITORING; HUMAN; INSOMNIA; NURSE ATTITUDE; NURSE PRACTITIONER; NURSING; NURSING ASSESSMENT; ORGANIZATION AND MANAGEMENT; PATIENT EDUCATION; PATIENT SELECTION; PRESCRIPTION; PSYCHOLOGICAL ASPECT; QUALITY OF LIFE; REVIEW; SAFETY;

CHEMISTRY, PHARMACEUTICAL; DELAYED-ACTION PREPARATIONS; DRUG MONITORING; HUMANS; HYPNOTICS AND SEDATIVES; NURSE PRACTITIONERS; NURSE'S ROLE; NURSING ASSESSMENT; PATIENT EDUCATION AS TOPIC; PATIENT SELECTION; PRESCRIPTIONS, DRUG; PYRIDINES; QUALITY OF LIFE; SAFETY; SLEEP INITIATION AND MAINTENANCE DISORDERS;

EID: 38949216040     PISSN: 10412972     EISSN: 17457599     Source Type: Journal    
DOI: 10.1111/j.1745-7599.2007.00279.x     Document Type: Review

References (44)

1. AMBIEN-CR™ 2005). Prescribing information. Retrieved November 8, 2005, from http://products.sanofi-aventis.us/ambien_cr/ambien_cr.pdf
2. American Academy of Sleep Medicine (Ed 2005). International classification of sleep disorders: Diagnostic and coding manual (2nd ed Westchester, IL : Author.
3. American Psychiatric Association 2000). Diagnostic and statistical manual of mental disorders (4th edition Text Revision ed Washington, DC : Author.
4. Ancoli-Israel, S. Cooke, J. R 2005). Prevalence and comorbidity of insomnia and effect on functioning in elderly populations. Journal of the American Geriatrics Society, 53 (7 Suppl S264 S271.
5. Ancoli-Israel, S. Roth, T 1999). Characteristics of insomnia in the United States: Results of the 1991 National Sleep Foundation Survey. I. Sleep, 22 (Suppl. 2 S347 S353.
6. Balter, M. B. Uhlenhuth, E. H 1992). New epidemiologic findings about insomnia and its treatment. Journal of Clinical Psychiatry, 53 (Suppl 34 39 discussion 40-32.
7. Blin, O., Micallef-Roll, J., Audebert, C. Legangneux, E 2006). A double-blind, placebo- and flurazepam-controlled investigation of the residual psychomotor and cognitive effects of modified release zolpidem in young healthy volunteers. Journal of Clinical Psychopharmacology, 26, 284 289.
8. Buysse, D. J., Finn, L. Young, T 2004). Onset, remission, persistence, and consistency of insomnia symptoms over 10 years: Longitudinal results from the Wisconsin Sleep Cohort Study (WSCS). Sleep, 27, A268. Abstract 602.
9. Dorsey, C. M., Lee, K. A. Scharf, M. B 2004). Effect of zolpidem on sleep in women with perimenopausal and postmenopausal insomnia: A 4-week, randomized, multicenter, double-blind, placebo-controlled study. Clinical Therapeutics, 26, 1578 1586.
10. Drake, C. L., Roehrs, T. Roth, T 2003). Insomnia causes, consequences, and therapeutics: An overview. Depression and Anxiety, 18, 163 176.
11. Erman, M., Krystal, A., Zammit, G., Soubrane, C. Roth, T 2006, July 9-13). Zolpidem extended-release 12.5 mg, taken for 24 weeks "as needed" up to 7 nights/week, improves subjective measures of therapeutic global impression, sleep onset, and sleep maintenance in patients with chronic insomnia. Paper presented at the Collegiume Internationale Neuro- Psychopharmacologicum (CINP), Chicago, IL.
12. Estivill, E 2003). Behavior of insomniacs and implication for their management. Sleep Medicine Reviews, 6, S3 6.
13. Gangwisch, J. E., Malaspina, D., Boden-Albala, B. Heymsfield, S. B 2005). Inadequate sleep as a risk factor for obesity: Analyses of the NHANES I. Sleep, 28, 1289 1296.
14. Goolsby, M. J 2006). AANP insomnia surveys: Sleep uncovered. Journal of the American Academy of Nurse Practitioners, 18, 557 558.
15. Hasler, G., Buysse, D. J., Klaghofer, R., Gamma, A., Ajdacic, V., Eich, D., et al 2004). The association between short sleep duration and obesity in young adults: A 13-year prospective study. Sleep, 27, 661 666.
16. Hindmarch, I 2006). A double-blind, placebo-controlled investigation of the residual psychomotor and cognitive effects of zolpidem-MR in healthy elderly subjects. British Journal of Clinical Pharmacology, 62, 538 545.
17. Hindmarch, I., Stanley, N., Legangneux, E. Emegbo, S 2005). Zolpidem modified-release 12.5 mg improves measures of sleep continuity in a model of sleep disturbance (traffic noise) compared with standard zolpidem 10 mg. Pharmacotherapy, 25, 1504. Abstract 1321.
18. Hohagen, F., Kappler, C., Schramm, E., Riemann, D., Weyerer, S. Berger, M 1994). Sleep onset insomnia, sleep maintaining insomnia and insomnia with early morning awakening - Temporal stability of subtypes in a longitudinal study on general practice attenders. Sleep, 17, 551 554.
19. Kales, A., Bixler, E. O., Soldatos, C. R., Vela-Bueno, A., Jacoby, J. Kales, J. D 1982). Quazepam and flurazepam: Long-term use and extended withdrawal. Clinical Pharmacology and Therapeutics, 32, 781 788.
20. Kales, A., Scharf, M. B., Kales, J. D. Soldatos, C. R 1979). Rebound insomnia. A potential hazard following withdrawal of certain benzodiazepines. JAMA, 241, 1692 1695.
21. Krystal, A. D., Walsh, J. K., Laska, E., Caron, J., Amato, D. A., Wessel, T. C. Roth, T 2003). Sustained efficacy of eszopiclone over 6 months of nightly treatment: Results of a randomized, double-blind, placebo-controlled study in adults with chronic insomnia. Sleep, 26 : 793 799.
22. Leese, P., Maier, G. Vaickus, L 2002). Eszopiclone: Pharmacokinetic and pharmacodynamic effects of a novel sedative hypnotic after daytime administration in healthy subjects. Sleep, 25 (Suppl Abstract A45.
23. Mendelson, W. B., Roth, T., Cassella, J., Roehrs, T., Walsh, J. K., Woods, J. H., et al 2004). The treatment of chronic insomnia: Drug indications, chronic use and abuse liability. Summary of a 2001 New Clinical Drug Evaluation Unit meeting symposium. Sleep Medicine Reviews, 8, 7 17.
24. Montgomery, P. Dennis, J 2004). A systematic review of non-pharmacological therapies for sleep problems in later life. Sleep Medicine Reviews, 8, 47 62.
25. Morin, C. M., Hauri, P. J., Espie, C. A., Spielman, A. J., Buysse, D. J. Bootzin, R. R 1999). Nonpharmacologic treatment of chronic insomnia. An American Academy of Sleep Medicine review. Sleep, 22, 1134 1156.
26. National Institutes of Health 2005). State of the Science Conference statement on manifestations and management of chronic insomnia in adults. Sleep, 28, 1049 1057.
27. National Sleep Foundation 2005). Sleep in America Poll [online]. Retrieved January 27, 2006, from www.sleepfoundation.org
28. Ohayon, M 2002). Epidemiology of insomnia: What we know and what we still need to learn. Sleep Medicine Reviews, 6, 97 111.
29. Roehrs, T., Soubrane, C., Walsh, J. Roth, T 2005). Zolpidem modified-release objectively and subjectively improves sleep maintenance and retains the characteristics of standard zolpidem on sleep initiation and duration in elderly patients with primary insomnia. Sleep, 28 (Suppl A244. Abstract 0725.
30. Roth, T., Roehrs, T. Vogel, G 1995). Zolpidem in the treatment of transient insomnia: A double-blind, randomized comparison with placebo. Sleep, 18, 246 251.
31. Roth, T., Soubrane, C., Titeux, L. Walsh, J. K 2006). Efficacy and safety of zolpidem MR: A double-blind, placebo-controlled study in adults with primary insomnia. Sleep Medicine, 7, 397 406.
32. Rudolph, U., Crestani, F., Benke, D., Brunig, I., Benson, J. A., Fritschy, J. M., et al 1999). Benzodiazepine actions mediated by specific gamma-aminobutyric acid(A) receptor subtypes. Nature, 401 (6755 796 800.
33. Sanger, D. J., Benavides, J., Perrault, G., Morel, E., Cohen, C., Joly, D., et al 1994). Recent developments in the behavioral pharmacology of benzodiazepine (omega) receptors: Evidence for the functional significance of receptor subtypes. Neuroscience and Biobehavioral Reviews, 18, 355 372.
34. Sanger, D. J. Zivkovic, B 1992). Differential development of tolerance to the depressant effects of benzodiazepine and non-benzodiazepine agonists at the omega (BZ) modulatory sites of GABAA receptors. Neuropharmacology, 31, 693 700.
35. Sateia, M. J. Pigeon, W. R 2004). Identification and management of insomnia. Medical Clinics of North America, 88, 567 596, vii.
36. Scharf, M. B., Roth, T., Vogel, G. W. Walsh, J. K 1994). A multicenter, placebo-controlled study evaluating zolpidem in the treatment of chronic insomnia. Journal of Clinical Psychiatry, 55, 192 199.
37. Schubert, C. R., Cruickshanks, K. J., Dalton, D. S., Klein, B. E., Klein, R. Nondahl, D. M 2002). Prevalence of sleep problems and quality of life in an older population. Sleep, 25, 889 893.
38. Summers, M. O., Crisostomo, M. I. Stepanski, E. J 2006). Recent developments in the classification, evaluation, and treatment of insomnia. Chest, 130, 276 286.
39. Tansella, C. Z., Tansella, M. Lader, M 1979). A comparison of the clinical and psychological effects of diazepam and amylobarbitone in anxious patients. British Journal of Clinical Pharmacology, 7, 605 611.
40. Walsh, J. K 2004). Clinical and socioeconomic correlates of insomnia. Journal of Clinical Psychiatry, 65 (Suppl. 8 13 19.
41. Walsh, J. K., Fry, J. Erwin, C. W 1998). Efficacy and tolerability of 14-day administration of zaleplon 5 mg and 10 mg for the treatment of primary insomnia. Clinical Drug Investigations, 16, 347 354.
42. Weinling, E., McDougall, S., Andre, F., Bianchetti, G., Dubruc, C. Krupka, E 2006). Pharmacokinetic profile of a new modified release formulation of zolpidem designed to improve sleep maintenance. Fundamental and Clinical Pharmacology, 20, 397 403.
43. Wheatley, D 2005). Medicinal plants for insomnia: A review of their pharmacology, efficacy and tolerability. Journal of Psychopharmacology, 19, 414 421.
44. Zammit, G., Erman, M., Krystal, A., Soubrane, C. Roth, T 2006). 6-month evaluation of zolpidem extended-release 12.5 mg in adult patients with primary insomnia: Improvements in next-day functioning with no observed tolerance and no rebound insomnia. Pharmacotherapy, 26 (10 Abstract 258.